<SEC-DOCUMENT>0001178913-20-000606.txt : 20200220
<SEC-HEADER>0001178913-20-000606.hdr.sgml : 20200220
<ACCEPTANCE-DATETIME>20200220070013
ACCESSION NUMBER:		0001178913-20-000606
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20200220
FILED AS OF DATE:		20200220
DATE AS OF CHANGE:		20200220

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30902
		FILM NUMBER:		20632509

	BUSINESS ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
		BUSINESS PHONE:		011-972-3-765-8585

	MAIL ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2024034.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using EDGARfilings PROfile 6.5.1.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Washington, D.C. 20549</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">Form 6-K</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">For the month of February 2020</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">Commission File Number 000-30902</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">COMPUGEN LTD.</div>
    <div style="text-align: center; line-height: 1.25;">(Translation of registrant&#8217;s name into English)</div>
    <table cellspacing="0" cellpadding="0" id="z52ca19e4e10c4524bfb14c4516222fc5" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 100%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">26&#160;Harokmim Street</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Holon 5885849, Israel</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25;">(Address of Principal Executive Offices)&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Form 20-F &#9746; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Form 40-F &#9744;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;<br>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Compugen Ltd.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">On February 14, 2020, Compugen Ltd. (&#8220;<font style="font-weight: bold;">Compugen</font>&#8221;
      or the &#8220;<font style="font-weight: bold;">Company</font>&#8221;) entered into an amendment (the &#8220;<font style="font-weight: bold;">Amendment</font>&#8221;)
      to the Master Clinical Trial Collaboration Agreement dated October 10, 2018 (the &#8220;<font style="font-weight: bold;">Agreement</font>&#8221;) by and between the Company and Bristol-Myers Squibb
      Company, a Delaware corporation (&#8220;<font style="font-weight: bold;">Bristol-Myers Squibb&#8221;</font> or &#8220;<font style="font-weight: bold;">BMS</font>&#8221;). A copy of the press release announcing the amendment is furnished as Exhibit 99.1 to this Form 6-K.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Under the Agreement, the parties agreed to evaluate the safety and tolerability of Compugen&#8217;s COM701, a first-in-class investigational
      anti-PVRIG antibody (&#8220;<font style="font-weight: bold;">COM701</font>&#8221; or the &#8220;<font style="font-weight: bold;">Compugen
        Compound</font>&#8221;), in combination with Bristol-Myers Squibb&#8217;s programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors. As previously disclosed, the collaboration was also designed to address
      potential future combinations, including trials sponsored by Bristol-Myers Squibb to investigate combined inhibition of checkpoint mechanisms, such as PVRIG and TIGIT. Each study carried out pursuant to the Agreement is referred to as a &#8220;<font style="font-weight: bold;">Combined Therapy Study.</font>&#8221;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Under the Amendment, the parties have agreed to initiate a triple combination study to evaluate the safety and tolerability of COM701,
      Opdivo&#174;, and BMS&#8217; anti-TIGIT antibody known as BMS-986207 (collectively, the &#8220;<font style="font-weight: bold;">Triple Combination</font>&#8221;),&#160; instead of the planned expansion of the
      Combined Therapy Study designed to evaluate the dual combination of COM701 and Opdivo&#174;. Pursuant to the Amendment, instead of sponsoring the expansion of the Combined Therapy Study designed to evaluate the dual combination of COM701 and Opdivo&#174;,
      Compugen will be responsible for and will sponsor a two-part Phase 1/2 trial which includes the evaluation of the Triple Combination, in <font style="background-color: #FFFFFF;">patients
        with advanced solid tumors</font>. BMS will provide Opdivo&#174; and BMS-986207 at no cost to Compugen for this trial.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">As previously agreed, ownership of, and global commercial rights to, the Compugen Compound remain solely with Compugen (subject to the
      rights granted to BMS as hereinafter described). Pursuant to the Amendment, if Compugen wishes to license the right to commercialize the Compugen Compound in any territory during the time prior to the end of the Triple Combination plus six months
      (the &#8220;<font style="font-weight: bold;">Exclusivity Period</font>&#8221;), Compugen must first negotiate with BMS, for a period of three months (the &#8220;<font style="font-weight: bold;">Negotiation Period</font>&#8221;), to grant an exclusive license to develop and commercialize the Compugen Compound in that territory. If BMS and Compugen do not reach an agreement for an exclusive
      license within the Negotiation Period, then BMS will have no further first negotiation rights, and Compugen will be free to license the Compugen Compound (subject to the exclusivity provisions and all other rights afforded to BMS under the Agreement)
      to other parties, in such territory. After the expiration of the Exclusivity Period, Compugen is free to license the Compugen Compound without any further obligation to BMS.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">All other terms of the Agreement remain unchanged.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">The information contained in this Report on Form 6-K is hereby incorporated by reference into the Company&#8217;s Registration Statement on Form
      F-3, File No. <font style="background-color: #FFFFFF;">333-23300</font>1.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Exhibits</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="line-height: 1.25; font-weight: bold;">
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="zcd66f7eb19664d43a9c697965550401f">

          <tr>
            <td style="width: 7%;">
              <div>
                <div style="text-align: left; line-height: 1.25; font-weight: bold;">Exhibit</div>
                <div style="text-align: left; line-height: 1.25;"><font style="font-weight: bold;"><u>Number</u></font></div>
              </div>
            </td>
            <td style="width: 93%; text-align: left; vertical-align: bottom;">
              <div><font style="font-weight: bold; font-family: 'Times New Roman',Times,serif;"><u>Description of Exhibit</u></font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 7%; text-align: left; vertical-align: bottom;" rowspan="1"><a href="exhibit_10-1.htm"><font style="font-family: 'Times New Roman',Times,serif;">10.1</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">#</sup></a></td>
            <td style="width: 93%; text-align: left; vertical-align: bottom;" rowspan="1">&#160;
              <div><a href="exhibit_10-1.htm">Amendment No. 1 to Master Clinical Trial Collaboration Agreement, dated February 14, 2020, by and between Compugen
                    Ltd. and Bristol-Myers Squibb Company.</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 7%; text-align: left; vertical-align: bottom;" rowspan="1"><a href="exhibit_99-1.htm">99.1</a></td>
            <td style="width: 93%; text-align: left; vertical-align: bottom;" rowspan="1">&#160;
              <div><a href="exhibit_99-1.htm">Press Release dated February 20, 2020.</a></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25; font-weight: bold;"> </div>
    <div style="line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z7f658c8b3e2f4bf59e8dd0dc5976e2b9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div style="line-height: 1.25;">#</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">Portions of this exhibit (indicated by asterisks) have been omitted because the Registrant has determined they are not material and
              would likely cause competitive harm to the Registrant if publicly disclosed, and certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant hereby undertakes to furnish supplementally a copy
              of any omitted exhibit or schedule upon request by the Securities and Exchange Commission.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Signatures</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
      by the undersigned thereunto duly authorized.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z5be7441e914e4e1cb1590df02a7c7403" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 46%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="vertical-align: bottom;" colspan="3">
            <div style="line-height: 1.25; font-weight: bold;">COMPUGEN LTD.</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: middle;" colspan="4">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 46%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Date: February 20, 2020</div>
          </td>
          <td style="width: 4%; vertical-align: bottom;">
            <div style="line-height: 1.25;">By:&#160;</div>
          </td>
          <td style="width: 38.3%; vertical-align: bottom; border-bottom: 2px solid black;">
            <div style="line-height: 1.25;">/s/ Eran Ben Dor&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 46%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 38.3%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Eran Ben Dor</div>
            <div style="line-height: 1.25;">General Counsel</div>
          </td>
          <td style="width: 12%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit_10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using EDGARfilings PROfile 6.5.1.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-family: 'Times New Roman',Times,serif;"> </font>
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"> <font style="font-family: 'Times New Roman',Times,serif;"><u><font style="font-weight: bold;">Exhibit 10.1 </font></u></font></div>
    <div> <font style="font-family: 'Times New Roman',Times,serif;"><br>
      </font></div>
    <div>
      <div id="DSPFPageHeader">
        <table cellspacing="0" cellpadding="0" id="z69d70605d1a2422394a2faaf3136b44c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 100%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                <div style="text-align: right; margin-left: 1pt; line-height: 1.25;">EXECUTION COPY</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><br>
        <font style="background-color: #FFFFFF;">Certain confidential information contained in this document, marked by [*], has been omitted because Compugen Ltd. has determined that the information is (i) not material and (ii) would likely cause
          competitive harm to Compugen Ltd. if publicly disclosed.</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',serif; font-size: 9.5pt; font-weight: bold; text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">A</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">MENDMENT NO. 1 TO MASTER CLINICAL TRIAL COLLABORATION AGREEMENT</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="margin: 0px 0px; line-height: 1.25; text-align: justify; text-indent: 41.95pt;"><font style="font-family: 'Times New Roman',Times,serif;">T</font><font style="font-family: 'Times New Roman',Times,serif;">HIS AMENDMENT NO. 1 TO MASTER
          CLINICAL TRIAL COLLABORATION AGREEMENT</font> (this &#8220;<font style="font-weight: bold; font-style: italic;">Amendment</font>&#8221;) is effective as of February 14, 2020 (&#8220;<font style="font-weight: bold; font-style: italic;">Amendment Effective Date</font>&#8221;)

        by and between <font style="font-weight: bold;">Compugen Ltd.</font>, an Israeli corporation with a place of business at Azrieli Center, 26 Harokmim Street, Building D, Holon 5885849, Israel (&#8220;<font style="font-weight: bold;">Compugen</font>&#8221;),
        and <font style="font-weight: bold;">Bristol-Myers Squibb Company</font>, a Delaware corporation, headquartered at 430 E. 29th Street, 14FL, New York, N.Y. 10016 (&#8220;<font style="font-weight: bold;">BMS</font>&#8221;).</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: center; margin-right: 173pt; margin-left: 173pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9.5pt; font-weight: bold;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">B</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">ACKGROUND</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-indent: 36pt; margin-left: 6pt; line-height: 1.25;">A.<font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;BMS and Compugen entered into that certain Master Clinical Trial Collaboration Agreement, dated as of October
          10, 2018 (the &#8220;<font style="font-weight: bold; font-style: italic;">Agreement</font>&#8221;).</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; margin-right: 6pt; margin-left: 6pt; line-height: 1.25;">B.<font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Parties have mutually agreed to amend the Agreement as follows in accordance with
          Section 13.7 of the Agreement.</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 5.85pt; margin-left: 5.95pt; line-height: 1.25;">NOW, THEREFORE, in consideration of the mutual covenants and undertakings contained herein, and on the terms and subject to the
        conditions set forth herein, the Parties hereby agree as follows:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; margin-right: 5.95pt; margin-left: 6pt; line-height: 1.25;">1.<font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Capitalized terms used and not otherwise defined herein shall have the meaning given to
          such terms in the Agreement.</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="line-height: 1.25;">
        <div>
          <table cellspacing="0" cellpadding="0" id="zb487c455b9894bcaa74aaf259a320c8c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 42pt; font-family: 'Times New Roman',Times,serif;"><br>
                </td>
                <td style="width: 29.15pt; vertical-align: top; align: right;">2.</td>
                <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div>&#160;Section 1.34 shall be deleted in its entirety from the Agreement.</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; margin-left: 6pt; line-height: 1.25;">3.<font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The definition of &#8220;Exclusive Collaboration Period&#8221; as set forth in Section 1.48 is hereby amended and restated
          in its entirety as follows:</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="line-height: 1.25">
        <div style="line-height: 1.25;">
          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 42pt; font-family: 'Times New Roman',Times,serif;">&#8220;1.48</td>
                  <td style="width: 29.15pt; vertical-align: top; align: right;"><br>
                  </td>
                  <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                    <div>
                      <div style="text-align: justify; line-height: 1.25;">&#8220;<font style="font-weight: bold;">Exclusive Collaboration Period</font>&#8221; means the period commencing on the Effective Date and ending on the earliest of:</div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div>
          <table cellspacing="0" cellpadding="0" id="z9745a9396c5442be9e8088b795be5d8a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 73.65pt; font-family: 'Times New Roman',Times,serif;"><br>
                </td>
                <td style="width: 22.35pt; vertical-align: top; align: right;">(a)</td>
                <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div>six (6) months after Study Completion of the Triple Study as set forth in Study Plan No. 2; or</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="line-height: 1.25;">
        <div>
          <table cellspacing="0" cellpadding="0" id="z4de7652ca059467abe06847db9d4a977" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 72.95pt; font-family: 'Times New Roman',Times,serif;"><br>
                </td>
                <td style="width: 23.05pt; vertical-align: top; align: right;">(b)</td>
                <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div>the effective date of termination of this Agreement pursuant to Section 12.2, Section 12.3 or Section 12.4.&#8221;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; margin-right: 5.95pt; margin-left: 6pt; line-height: 1.25;">4.<font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Study Plan No. 1 previously attached to the Agreement is hereby replaced with the revised
          Study Plan No. 1 attached as <u>Attachment A </u>hereto.</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-indent: 36pt; margin-left: 6pt; line-height: 1.25;">5.<font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Clause (a) of <u>Exhibit E </u>to the Agreement is hereby amended and restated in its entirety as follows:</font></div>
      <div style="text-indent: 36pt; margin-left: 6pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"> <br>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><font style="background-color: #FFFFFF;">Certain confidential information contained in this document, marked by [*], has been omitted because Compugen Ltd. has determined that
            the information is (i) not material and (ii) would likely cause competitive harm to Compugen Ltd. if publicly disclosed.</font></div>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <div style="text-align: justify; text-indent: 36pt; margin-right: 5.7pt; margin-left: 6pt; line-height: 1.25;">
        <div id="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 100%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: right; margin-left: 1pt; line-height: 1.25;">EXECUTION COPY</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 5.7pt; margin-left: 6pt; line-height: 1.25;"> <font style="font-family: 'Times New Roman',Times,serif;"><br>
        </font></div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 5.7pt; margin-left: 6pt; line-height: 1.25;">&#8220;Neither Party is obligated to conduct additional studies of the Combined Therapy with the other Party upon completion of a Combined
        Therapy Study, subject to the following provisions of this Exhibit E; provided that the provisions of this Exhibit E are not applicable to any Combined Therapy Study other than the Triple Study. The provisions as set forth in this Exhibit E shall
        only be in effect (and the Parties will only have the rights set forth below in this Exhibit E) with respect to each Subsequent Study for which (x) the proposed protocol synopsis has been submitted by the Proposing Party to the Other Party (as set
        forth below) within the earlier of (i) [*] or (ii) [*]; provided that the proposed Subsequent Study must be commenced [*] within [*] of such protocol synopsis being provided to the Other Party and (y) at the time the proposed protocol synopsis has
        been submitted by the Proposing Party to the Other Party (as set forth below), the Other Party&#8217;s Compound is commercialized or in active development; <font style="font-style: italic;">provided </font>that, in the case of BMS, both of the BMS
        Compounds included in the Triple Study must be commercialized or in active development. For clarity, a Subsequent Study may be conducted only for a Combined Therapy for which the Parties agreed to conduct a Combined Therapy Study under this
        Agreement; provided that neither Party has the rights or obligations set forth below in this Exhibit E with respect to any Combined Therapy Study other than the Triple Study. For clarity, if Compugen conducts a study of a therapy using both the
        Compugen Compound and the BMS Compound in addition to the Combined Therapy Study as described in Study Plan No. 1 and BMS does not supply any BMS Compound pursuant to this Agreement for such study, such study shall not be considered a Combined
        Therapy Study pursuant to this Agreement.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; margin-right: 6pt; margin-left: 6pt; line-height: 1.25;">6.<font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Clause (d)(iv) of <u>Exhibit E </u>to the Agreement is hereby amended and restated in its
          entirety as follows:</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; margin-right: 5.85pt; margin-left: 5.95pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">(iv) </font>for the Subsequent Studies where Compugen is the non-Participating Other Party, [*]&#8221;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; margin-right: 6pt; margin-left: 6pt; line-height: 1.25;">7.<font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Clause (d)(v) of <u>Exhibit E </u>to the Agreement is hereby amended and restated in its
          entirety as follows:</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; margin-right: 5.75pt; margin-left: 6pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">(v) </font>for the Subsequent Studies where BMS is the non-Participating Other Party, [*]</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; margin-right: 5.85pt; margin-left: 6pt; line-height: 1.25;">8.<font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as amended by this Amendment, the Agreement shall continue in full force and
          effect pursuant to its terms.</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; margin-right: 5.95pt; margin-left: 6pt; line-height: 1.25;">9.<font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Amendment may be executed in two (2) or more counterparts, each of which shall be
          deemed an original, but all of which together shall constitute one (1) and the same instrument. This Amendment may be executed by facsimile or electronic (e.g., .pdf) signatures and such signatures shall be deemed to bind each Party hereto as if
          they were original signature.</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; margin-left: 6pt; line-height: 1.25;">10.<font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; This Amendment shall be governed and construed in accordance with the internal laws of the State of New York,
          USA, excluding any choice of law rules that may direct the application of the laws of another jurisdiction.</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">[Signature page follows]</div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;"> <font style="font-family: 'Times New Roman',Times,serif;"><br>
        </font></div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">
        <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold; font-style: normal;">
          <div style="line-height: 1.25; font-weight: bold;"><font style="background-color: #FFFFFF;">Certain confidential information contained in this document, marked by [*], has been omitted because Compugen Ltd. has determined that the information is
              (i) not material and (ii) would likely cause competitive harm to Compugen Ltd. if publicly disclosed.</font></div>
        </div>
        <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold; font-style: normal;"><font style="background-color: #FFFFFF;"> <br>
          </font></div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">2</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
      </div>
      <div id="DSPFPageHeader">
        <table cellspacing="0" cellpadding="0" id="z2896ca753ae44b15aeb85083129cc8b9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 100%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                <div style="text-align: right; margin-left: 1pt; line-height: 1.25;">EXECUTION COPY</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-indent: 36pt; margin-right: 5.25pt; margin-left: 9.95pt; line-height: 1.25;">IN WITNESS WHEREOF, BMS and Compugen have duly executed this Amendment as of the Amendment Effective Date.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="z4edace26ace54b0c8aa06f449f95d350" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 38.89%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="margin-left: 10pt; line-height: 1.25; font-weight: bold;">COMPUGEN LTD.</div>
            </td>
            <td style="width: 61.11%; vertical-align: top;">
              <div style="margin-left: 68.25pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9.5pt; font-weight: bold;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">B</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">RISTOL-MYERS SQUIBB COMPANY</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 38.89%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
            <td style="width: 61.11%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 38.89%; vertical-align: top;">
              <div style="margin-left: 10pt; line-height: 1.25;">By: _______________________________</div>
            </td>
            <td style="width: 61.11%; vertical-align: top;">
              <div style="margin-left: 68.25pt; line-height: 1.25;">By: _______________________________<font style="font-family: 'Times New Roman',Times,serif;"><br>
                </font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 38.89%; vertical-align: top;">
              <div style="margin-left: 10pt; line-height: 1.25;">Name: _____________________________</div>
            </td>
            <td style="width: 61.11%; vertical-align: top;">
              <div style="margin-left: 68.25pt; line-height: 1.25;">Name: _____________________________<font style="font-family: 'Times New Roman',Times,serif;"><br>
                </font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 38.89%; vertical-align: top;">
              <div style="margin-left: 10pt; line-height: 1.25;">Title: ______________________________</div>
            </td>
            <td style="width: 61.11%; vertical-align: top;">
              <div style="margin-left: 68.25pt; line-height: 1.25;">Title: ______________________________<font style="font-family: 'Times New Roman',Times,serif;"><br>
                </font></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><font style="background-color: #FFFFFF;">Certain confidential information contained in this document, marked by [*], has been omitted because Compugen Ltd. has determined that
            the information is (i) not material and (ii) would likely cause competitive harm to Compugen Ltd. if publicly disclosed.</font></div>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">3</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 100%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                <div style="text-align: right; margin-left: 1pt; line-height: 1.25;">EXECUTION COPY</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      </div>
      <div style="text-align: center; line-height: 1.25;"><u>Attachment A</u></div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">STUDY PLAN NO. 1<br>
      </div>
      <div style="text-align: center; line-height: 1.25;">[*]</div>
      <div style="text-align: center; line-height: 1.25;"> <font style="font-family: 'Times New Roman',Times,serif;"><br>
        </font></div>
      <div style="text-align: center; line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><font style="background-color: #FFFFFF;">Certain confidential information contained in this document, marked by [*], has been omitted because Compugen Ltd. has determined that
            the information is (i) not material and (ii) would likely cause competitive harm to Compugen Ltd. if publicly disclosed.</font></div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><font style="background-color: #FFFFFF;"> <br>
          </font></div>
      </div>
    </div>
  </div>
  <font style="font-family: 'Times New Roman',Times,serif;"> </font>
  <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">4</font>
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using EDGARfilings PROfile 6.5.1.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div id="DSPFPageHeader">
      <div style="line-height: 1.25; text-align: right;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u><font style="font-weight: bold;">Exhibit 99.1</font></u><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="background-color: #FFFFFF; line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><img src="image00001.jpg">
        <div><br>
        </div>
      </div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">FOR IMMEDIATE RELEASE</div>
    <div style="background-color: #FFFFFF; line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="background-color: #FFFFFF; line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Compugen Announces Phase 1/2 Triple Combination Study to Evaluate </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">COM701 in Combination with Bristol-Myers Squibb&#8217;s Opdivo&#174; </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">(Nivolumab) and TIGIT Inhibitor</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">Triple combination study intended to evaluate Compugen&#8217;s PVRIG pathway discovery </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">and DNAM axis hypothesis in patients with advanced solid tumors</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">Study expected to commence in the second half of 2020</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">Company will host conference call today at 8:30 AM ET</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">HOLON, Israel &#8211; February 20, 2020 &#8211; Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery,<font style="font-weight: bold;">&#160;</font>today announced its plan
      to initiate a Phase 1/2 study evaluating a triple combination of Compugen&#8217;s COM701, an investigational anti-PVRIG antibody, in combination with Bristol-Myers Squibb&#8217;s PD-1 immune checkpoint inhibitor <font style="font-style: italic;">Opdivo</font>&#174;
      (nivolumab)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#160;</sup>and BMS-986207, Bristol-Myers Squibb&#8217;s investigational anti-TIGIT antibody.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">The triple combination study is designed to evaluate the blockade of the three immune checkpoint pathways &#8211; PVRIG, TIGIT and PD-1, and will accelerate the clinical evaluation of Compugen&#8217;s science-driven DNAM axis
      hypothesis in various advanced solid tumors. The study is expected to commence in the second half of 2020, following the clearance of a new Investigational New Drug Application by the U.S. Food and Drug Administration. Compugen will be the study
      sponsor with Opdivo&#174; and BMS-986207 supplied by Bristol-Myers Squibb.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">&#8220;We are excited to expand our collaboration with Bristol-Myers Squib with this biomarker-informed triple combination study to accelerate the clinical evaluation of COM701,&#8221; said Anat Cohen-Dayag, Ph.D., President and CEO
      of Compugen. &#8220;The triple combination regimen allows us to ultimately test our science-driven hypothesis that the dual inhibition of the DNAM axis with PVRIG and TIGIT blockers, together with the inhibition of the PD-1 pathway, will enable robust
      activation of T cells leading to anti-tumor immune responses in cancer patients who are non-responsive or refractory to PD-1 blockers.&#8221;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">&#8220;The initial encouraging signals of anti-tumor activity observed in heavily pretreated patients in the monotherapy dose escalation arm of our ongoing Phase 1 study, paired with our strong scientific rationale and
      preclinical data, support to our decision to evaluate whether the combination of these three immune checkpoint inhibitors improve patient outcomes and broaden the patient population that will respond to immunotherapies,&#8221; added Dr. Cohen-Dayag.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Under the existing collaboration with Bristol-Myers Squibb, COM701 is being investigated as a monotherapy and in combination with Opdivo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> in an ongoing Phase 1 study. Following the Companies&#8217; joint decision to
      move forward with a triple combination study, Compugen will complete the dose escalation arm of the dual combination of COM701 with Opdivo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> under its ongoing Phase 1 study. Future studies evaluating COM701 in combination with a PD-1
      inhibitor in specific tumor types will be assessed at a later date. As previously indicated, Compugen plans to present initial data from the combination dose escalation study of COM701 with Opdivo<sup style="font-style: italic; vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#160;</sup>in
      the second half of 2020. Compugen will continue to advance the biomarker informed monotherapy expansion arm of the ongoing COM701 Phase 1 study, as planned.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">The planned open-label Phase 1/2 trial is designed to evaluate the safety, tolerability and antitumor activity of COM701 in combination with Opdivo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174; </sup>and BMS-986207. The study will evaluate a safe and
      tolerable dose of the combination during dose escalation and antitumor activity in selected tumor types in the expansion cohorts (ovarian cancer, endometrial cancer and a biomarker-driven arm of tumor types with high expression of PVRL2).&#160; Dose
      levels for Opdivo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and BMS-986207 combinations have already been determined through prior testing by Bristol-Myers Squibb, allowing for dose escalation of COM701 with fixed doses of Opdivo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and BMS&#8209;986207.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-weight: bold;">About COM701</div>
    <div style="line-height: 1.25;">COM701 is a humanized antibody that binds with high affinity to PVRIG, a novel immune checkpoint discovered computationally by Compugen, blocking the interaction with its ligand, PVRL2. Blockade of PVRIG by COM701 has
      demonstrated potent, reproducible enhancement of T cell activation, consistent with the desired mechanism of action of activating T cells in the tumor microenvironment to generate anti-tumor immune responses. PVRIG and TIGIT, also discovered by
      Compugen&#8217;s computational discovery platform in 2009, constitute parallel immune checkpoint pathways that counteract DNAM, a costimulatory molecule on T cells and NK cells. As such, preclinical data suggest that the inhibition of PVRIG together with
      TIGIT and/or PD-1 has the potential to further enhance anti-tumor immune response and improve patient outcomes in a broad variety of tumor types.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">COM701 is being evaluated as a monotherapy and in combination with Opdivo&#174; (nivolumab), Bristol-Myers Squibb&#8217;s PD-1 inhibitor in a Phase 1 open-label clinical trial in patients with advanced solid tumors. Primary end
      points of the trial are safety and tolerability; secondary endpoints include preliminary anti-tumor activity, pharmacokinetics and pharmacodynamics in patients with selected tumor types. Data from the monotherapy dose escalation study (n=13)
      presented at SITC 2019 showed that COM701 is well-tolerated and demonstrated preliminary signs of anti-tumor activity in heavily pretreated patient population Additional information is available at www.clinicaltrials.gov (NCT03667716).</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Conference Call and Webcast Information</div>
    <div style="line-height: 1.25;">Compugen management will hold a conference call today, February 20, 2020, at 8:30 AM ET. To access the conference call by telephone, please dial 1-888-407-2553 from the United States, or +972-3-918-0610 internationally.
      The call will also be available via live webcast through Compugen&#8217;s website, located at the following link. Following the live audio webcast, a replay will be available on the Company&#8217;s website.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">About Compugen</div>
    <div style="line-height: 1.25;">Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the
      field of cancer immunotherapy. The Company&#8217;s lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen's antibody targeting TIGIT, is
      expected to enter the clinic in early 2020. The Company's therapeutic pipeline also includes early-stage immuno-oncology programs focused largely on myeloid targets. Compugen&#8217;s business model is to selectively enter into collaborations for its novel
      targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with offices in South San Francisco, CA. Compugen&#8217;s shares are listed on the Nasdaq and the Tel Aviv Stock Exchange
      under the ticker symbol CGEN. For additional information, please visit Compugen&#8217;s corporate website at www.cgen.com.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><font style="font-style: italic;">Opdivo&#174;</font> is a registered trademark of Bristol-Myers Squibb Company.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Forward Looking Statement</div>
    <div style="line-height: 1.25;">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private
      Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs, expectations and assumptions of Compugen. Forward-looking statements can be identified by the use of terminology such as &#8220;will,&#8221; &#8220;may,&#8221;
      &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;potential,&#8221; &#8220;plan,&#8221; &#8220;goal,&#8221; &#8220;estimate,&#8221; &#8220;likely,&#8221; &#8220;should,&#8221; &#8220;confident,&#8221; and &#8220;intends,&#8221; and similar expressions that are intended to identify forward-looking statements, although not all forward-looking
      statements contain these identifying words. Forward-looking statements include, but are not limited to, statements regarding Compugen&#8217;s expected schedule to commence the triple combination study, Compugen&#8217;s expected schedule to present initial data
      from the combination dose escalation study of COM701 with Opdivo<sup style="font-style: italic; vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, Compugen&#8217;s continuing to advance the monotherapy expansion arm of the ongoing COM701 Phase 1 study and the companies&#8217; planned cohorts for the
      open-label Phase 1/2 trial. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance
      or achievements expressed or implied by such forward-looking statements. Among these risks: Compugen may encounter substantial delays or even an inability to begin clinical trials for any specific product, or may not be able to conduct or complete
      its trials on the timelines expected and Compugen&#8217;s ability to present data derived from collaborations with its partners is dependent in some cases on the agreement of our partners to present such data, and Compugen&#8217;s business model is substantially
      dependent on entering into collaboration agreements with third parties.&#160; These risks and other risks are more fully described in the &#8220;Risk Factors&#8221; section of Compugen&#8217;s most recent Annual Report on Form 20-F filed with the Securities and Exchange
      Commission (SEC) as well as other documents that may be subsequently filed by Compugen from time to time with the SEC. In addition, any forward-looking statements represent Compugen&#8217;s views only as of the date of this release and should not be relied
      upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;"><u>Company contact</u>:</div>
    <div style="line-height: 1.25;">Elana Holzman</div>
    <div style="line-height: 1.25;">Director, Investor Relations and Corporate Communications</div>
    <div style="line-height: 1.25;">Compugen Ltd.</div>
    <div style="line-height: 1.25;">Email: elanah@cgen.com</div>
    <div style="line-height: 1.25;">Tel: +972 (3) 765-8124</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;"><u>Investor Relations contact</u>:</div>
    <div style="line-height: 1.25;">Bob Yedid</div>
    <div style="line-height: 1.25;">LifeSci Advisors, LLC<br>
      Email: bob@lifesciadvisors.com</div>
    <div style="line-height: 1.25;">Tel: +1 (646) 597-6989</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  L )H# 2(  A$! Q$!_\0
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EA>SE>_,4]'AO+>P2/4;E;FY!):0+M!YXXJ[116;=]35*RL?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
